GENE ONLINE|News &
Three Companies Received Orphan Drug Designations in One Day To Treat Rare Cancers
The FDA posted three new Orphan Drug Designations (ODD) on June 17 for two companies targeting brain cancer, Kazia and VBI, and one company targeting a type of liver cancer, Hepion. An orphan drug is a treatment targeting a disease that affects less than 200,000 people in the United States. All three companies will use the ODD and the associated benefits to further the development of their drugs targeting rare cancers.
It's free! Log in now to read
LATEST
Definium’s Psychedelic Anxiety Drug DT120 Moves Closer to the Mainstream With a Phase 3 Win
2026-08-14
JAMA Network Open Study Links Agent Orange and Burn Pit Exposure to Veteran Health Outcomes
2026-08-14
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
